|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|
|
$
|
(49,329
|
)
|
|
$
|
(1,076
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization expense
|
|
|
25
|
|
|
|
5
|
|
Amortization of debt discount
|
|
|
191
|
|
|
|
15
|
|
Change in fair value of contingent consideration liability- related parties
|
|
|
660
|
|
|
|
66
|
|
Change in fair value of short term notes receivable - related parties
|
|
|
|
|
|
|
(718
|
)
|
Change in fair value of convertible promissory notes
|
|
|
|
|
|
|
133
|
|
Change in fair value of derivative liability
|
|
|
(41
|
)
|
|
|
12
|
|
Change in fair value of
warrant liability
|
|
|
|
|
|
|
|
|
Unrealized
loss
on other investments
held at fair value
|
|
|
5,460
|
|
|
|
—
|
|
Unrealized gains on other investments
|
|
|
|
|
|
|
|
|
Gain on dilution of equity method investment
|
|
|
|
|
|
|
|
|
Loss on conversion of convertible notes
|
|
|
513
|
|
|
|
|
|
Gain on consolidation of a variable interest entity
|
|
|
|
|
|
|
|
|
Losses from investments in equity method investees
|
|
|
4,641
|
|
|
|
11,831
|
|
In-process research and development expense
|
|
|
8,934
|
|
|
|
120
|
|
Stock-based compensation
expense
|
|
|
37,724
|
|
|
|
82
|
|
Unrealized foreign exchange gains
|
|
|
|
|
|
|
(155
|
)
|
|
|
|
41
|
|
|
|
(57
|
)
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets
|
|
|
(1,674
|
)
|
|
|
(513
|
)
|
|
|
|
2,380
|
|
|
|
252
|
|
|
|
|
(3,846
|
)
|
|
|
752
|
|
|
|
|
120
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(14,627
|
)
|
|
|
(9,107
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
(298
|
)
|
|
|
(8
|
)
|
Capitalized internal-use software development costs
|
|
|
|
|
|
|
|
|
Cash acquired in asset acquisitions, net
|
|
|
47
|
|
|
|
—
|
|
Cash paid for investments in equity method investees
|
|
|
(5,359
|
)
|
|
|
—
|
|
Cash paid for other investments
|
|
|
(23,445
|
)
|
|
|
(17,823
|
)
|
Purchases of long term notes receivable - related party
|
|
|
|
|
|
|
(1,198
|
)
|
|
|
|
(2,624
|
)
|
|
|
—
|
|
Cash paid for other assets
|
|
|
(195
|
)
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(32,029
|
)
|
|
|
(19,029
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock
|
|
|
409,884
|
|
|
|
—
|
|
Cash paid for common stock issuance costs
|
|
|
(10,161
|
)
|
|
|
|
|
Proceeds from issuance of share option awards
|
|
|
534
|
|
|
|
—
|
|
Proceeds from sale of investment
|
|
|
2,417
|
|
|
|
—
|
|
Proceeds from issuance of convertible promissory notes
|
|
|
1,588
|
|
|
|
13,011
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
404,262
|
|
|
|
13,011
|
|
|
|
|
|
|
|
|
|
|
Effect of foreign exchange rate changes on cash
|
|
|
(1,230
|
)
|
|
|
(204
|
)
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
356,376
|
|
|
|
(15,329
|
)
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents – beginning of the period
|
|
|
97,246
|
|
|
|
30,062
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents – end of the period
|
|
$
|
453,622
|
|
|
|
14,733
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of non-cash investing and financing information:
|
|
|
|
|
|
|
|
|
Fair value of noncontrolling interests issued in connection with asset acquisitions
|
|
$
|
885
|
|
|
$
|
—
|
|
Fair value of noncontrolling interests issued in connection with consolidation of a VIE
|
|
|
|
|
|
|
|
|
Fair value redeemable noncontrolling interests issued in connection with consolidation of a VIE
|
|
|
|
|
|
|
|
|
Issuance of subsidiary shares in connection with the conversion of convertible notes
|
|
|
|
|
|
|
|
Common stock issuance costs in accounts payable
|
|
$
|
230
|
|
|
$
|
—
|
|
Common stock issuance costs in accrued liabilities
|
|
$
|
1,958
|
|
|
$
|
—
|
|
Conversion of short term notes receivable for other investments
|
|
$
|
—
|
|
|
$
|
9,003
|
|
Issuance of subsidiary shares in connection with a stock purchase agreement
|
|
$
|
|
|
|
$
|
120
|
|
Issuance of derivative instrument related to convertible promissory notes
|
|
$
|
646
|
|
|
$
|
203
|
|